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Abstract 
 
Inhibitory activity of a congeneric set of 23 phenyl-substituted 5-phenyl-pyrazole-3-
carboxylic acids toward human carbonic anhydrase (hCA, EC 4.2.1.1) isoforms I, II, IX 
and XII was evaluated by a stopped-flow CO2 hydrase assay. These compounds exerted a 
clear, selective inhibition of hCA IX and XII over hCAI and II, with Ki in two to one 
digit micromolar concentrations (4 – 50 µM). Derivatives bearing bulkier substituents in 
para-position of the phenyl ring inhibited hCA XII at one-digit micromolar 
concentrations, while derivatives having alkyl substituents in both ortho- and meta-
positions inhibited hCA IX with Kis ranging between 5 and 25 µM. Results of docking 
experiments offered a rational explanation on the selectivity of these compounds toward 
CA IX and XII, as well as on the substitution patterns leading to best CA IX or CA XII 
inhibitors. By examining the active sites of these four isoforms with GRID generated 
molecular-interaction fields, striking differences between hCA XII and the other three 
isoforms were observed. The field of hydrophobic probe (DRY) appeared significantly 
different in CA XII active site, comparing to other three isoforms studied. To the best of 
our knowledge such an observation was not reported in literature so far. Considering the 
selectivity of these carboxylates towards membrane-associated over cytosolic CA 
  
isoforms, the title compounds could be useful for the development of isoform-specific 
non-sulfonamide CA inhibitors. 
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1. Introduction: 
 
There are a few reports on biological activity of 5-aryl-pyrazole-3-carboxylic acid in the 
literature. Compounds were described as partial agonists of the nicotinic acid receptors,1
as inhibitors of replication protein A protein-protein interactions,2 as scaffolds that lead to 
inhibitors of protein tyrosine phosphatase 1B,3 and as an inhibitors of a tissue-nonspecific 
alkaline phosphatase.4 Along with this, 5-heteroaryl-pyrazole-3-carboxylic acids, among 
other compounds, were recently described as inhibitors of human carbonic anhydrases 
(CAs, EC 4.2.1.1) I, II, IX and XII.5  
The majority of reported small molecule CA inhibitors (CAIs) comprises a 
primary sulfonamide moiety as a zinc binding group (ZBG). The sulfonamide anion (-
SO2NH−) coordinates the active site Zn2+ ion and blocks catalysis. In Protein data bank 
more than 300 unique sulfonamide-bearing small molecules co-crystallized with carbonic 
anhydrases (mainly human isoform II) can be found. On the other hand, significantly less 
non-sulfonamide CAIs, belonging to other classes of small organic molecules, such as for 
example carboxylic acids, were investigated so far. It was shown that some molecules 
comprising -COOH moiety co-crystallized with different CA isoforms, are bound within 
the CA active site, interacting with the active site Zn2+ by water-mediated H-bonding, 
while other were found bound to the enzyme but did not interact with the active site Zn2+ 
ion, or they were bound out of the active site. Best examples of the latter are, probably, 
ortho-hydroxy cinnamic acids – mechanism-based inhibitors originated in situ by 
hydrolysis of coumarins by Zn2+ - hydroxyl ion couple in the CA active site.6,7,8,9  Isoform 
selectivity of this class of compounds depends on substitution pattern on coumarin phenyl 
ring. Recently reported 2-benzylsulfinylbenzoic acid10 was found bound to hCA II out of 
the active site. This compound constrained the proton-shuttle residue His64 in its ‘out’ 
conformation by a network of water molecules-mediated H-bonds. Inhibition study of 
hCA I and II, as well as mycobaterial and fungal CA with a library of natural products, 
found adduct of cinnamic and maleic acid amide, 3-(3-chloro-4-hydroxyphenyl)-2-[(4-
methoxy-4-oxobut-2-enoyl)amino]propanoic acid (CID 72785959, CAS 852690-88-1), as 
a low micromolar CA inhibitor.11 Structure of compound co-crystallized with hCA II 
revealed that carboxyl group of cinnamic acid moiety is not involved in interaction with 
catalytic Zn2+ ion. Inhibition of mycobacterial CA Rv3588c by (+)-mispyric acid, natural 
product bearing two carboxyl groups, was also described,12 without additional structural 
data. Smaller carboxylate-bearing molecules, such as hydroxy and thio-substituted 
benzoic acids, were found bound to the CA active site, forming hydrogen bond to the Zn-
bound water molecule/hydroxide ion.13 In the same crystal structures two more molecules 
of substituted benzoic acids were found, occupying protein cavities out of the binding 
site. Inhibition of CAs with biologically-relevant aliphatic carboxylates, along with 
benzoic and 1,2,5,6-tetrafluoro-benzoic acids were also described, without additional 
  
structural data.14 A congeneric set of di-methoxy-bromophenyl-substituted 2-benzyl-
cyclopropyl carboxylic acids and derivatives, having the same topological distance 
between aryl and carboxyl moieties as in a title compounds, were recently reported as 
inhibitors of human CA isoforms I, II, IX and XII.15 Those compounds exerted strong 
preferences toward hCA I and II inhibition. Carboxylic acid derivatives briefly described 
in the previous lines inhibited CAs with Kis spanning range between the milimolar to 
micromolar concentrations, with the exception of 2-benzyl-cyclopropyl carboxylic acids, 
found as nanomolar inhibitors.  
In this article we report the synthesis and inhibitory activity of a congeneric set of 
23 phenyl-substituted 5-phenyl-pyrazole-3-carboxylic acids (1-23) toward human CA 
isoforms I, II, IX and XII. 
 
2. Results and discussion: 
 
2.1 Chemistry: 
 
The rationale of this work was to investigate different chemotypes incorporating the 
COOH moiety as a ZBG for obtaining CAIs. As heterocyclic carboxylic acids were rarely 
investigated as CAIs, we decided to synthesize a congeneric series of such derivatives 
incorporating the synthetically easily available pyrazole-3-carboxylic acid moiety. 
Acetophenones II were prepared by Fridel-Crafts acylation of the corresponding 
aromatic substrates (I), or commercially available substances were used. The aryl-diketo 
acids III were prepared following previously reported procedures,16 by base-promoted 
condensations of substituted acetophenones (II) and diethyl-oxalate. Compounds 1-23 
(IV) were synthesized from aryldiketo acids (III) and hydrazine-hydrate in glacial acetic 
acid (Scheme 1).  
 
Scheme 1.  
 
Identity and purity of compounds was confirmed by 1H and 13C NMR spectroscopy and 
LC-HR/ESI-MS.  
 
2.2 Tautomeric preferences and protonation states: 
 
Aryl-pyrazole-carboxylic acid could appear in three tautomeric forms (Scheme 2). 
 
Scheme 2.  
 
Tautomers A and B, with protonated pyrazole nitrogens, are more probable than the 
tautomer C. In solid state, tautomeric form A was observed.17 To gather more data on 
tautomeric preferences of examined compounds in solution, we recorded NOESY spectra 
of 4-Me-derivative (1), in DMSO-d6. 4-Me-derivative (1) was chosen because of simple 
1H NMR pattern of protons on phenyl ring. Spectra were recorded in DMSO due to good 
solubility of examined compounds and its polarity, which preclude possible aggregation 
of solute by intramolecular H-bonding, observed in solid state (see below). Clear NOESY 
  
signal between broad 1H peak at 13.38 ppm and doublet at 7.71 ppm (Figure 1) was 
observed. 
 
Figure 1. 
 
Doublet at 7.71 ppm belongs to hydrogens in ortho-position of the phenyl ring, while 
broad signal at 13.38 ppm belongs to pyrazole NH. Those data suggested that tautomer A 
is principal one in DMSO solution. Upon addition of one molar equivalent of piperidine, 
to deprotonate carboxyl group, broad signal at 13.38 ppm was shifted to 9.75 ppm and 
NOESY signal disappeared (Figure S1 in Supplementary Material). Our preliminary 
results suggested that tautomeric form A should not be predominant one when carboxyl 
group of title compounds is in its anionic form, although it is well known that tautomeric 
preferences are different in different solvents. Tautomeric preferences of title compounds 
will be a subject of separate studies. IR spectra of compounds were obtained by ATR 
(attenuated total reflectance) from solid samples. In spectra of some compounds we 
clearly observed broad IR bands in the region 3100-3250 cm-1, where NH stretching 
bands were overlapped with aromatic C-H bands. Such pattern in IR spectra suggested 
aggregation via hydrogen bonding of some derivatives. Examples are given in 
Supplementary Material, Figure S2. This is in accordance with crystal structure of 
unsubstituted derivative,17 where in crystal packing intermolecular H-bonds between 
carboxyl group and pyrazole -NH-N= part is observed. We also estimated protonation 
states18 of compound 1 (Figure S3 in Supplementary Material). pKa Value of carboxyl 
group is predicted to be within the range 3.6 - 4.0; while pKa value of pyrazole nitrogen is 
predicted to be within the range 10.2 -10.7, depending on tautomeric state (Figure S4 in 
Supplementary Material). pKa1 Value (carboxyl group) of derivative 22 was 
experimentally determined using spectrophotometric titration. Three wavelengths used 
for spectrophotometric pKa1 determination (270, 280, 290 nm) were selected as 
wavelengths where the difference in absorptivity of species existing in the solution is 
maximal. The UV/Vis spectra and the graph used for the pKa1 value determination are 
shown in Figure 2. For details see Experimental part. The determined pKa1 of derivative 
22 is 3.31±0.07.   
 
Figure 2. 
 
2.3 CA inhibition 
 
Inhibitory activity of compounds toward hCA I, II, IX and XII was evaluated by a 
stopped-flow CO2 hydrase assay. Results are reported as Ki values (Table 1). 
 
Table 1. 
 
 
All compounds tested were proved to be inactive towards CA I and II, which were not 
inhibited up to concentrations of 50 µM inhibitor in the assay system. Depending on the 
substitution pattern on the phenyl ring, different subsets of compounds were active 
towards CA IX or towards CA XII. Along with Ki data reported in Table 1, strong 
  
selective inhibition of 1-23 toward CA IX and CA XII over CA I and II can be noted (see 
also Supplementary Table 1). Dose-response curves for inhibitory activity of these 
compounds toward all CA isoforms appeared rather flat, still percentage of enzyme 
activity of CA I and II were between 60 and 70 % even at 1×10-4 M concentrations of 
inhibitors. Providing selectivity toward membrane-associated CA isoforms, considered as 
a good anti-tumor targets,19 over cytosolic isoforms, the title compounds might be used as 
a good starting point for the design of isoform-selective inhibitors incorporating -COOH 
ZBGs. Compounds active toward CA IX and CA XII inhibited those two isoforms in 
one- to two-digit micromolar concentrations, comparable with the potency of the majority 
of so-far reported CA inhibitors bearing this ZBG.   
 
2.4 Structure-activity study 
 
In an attempt to explain selectivity of some of these compounds toward CA IX and CA 
XII and to explain preferences of different subsets of compounds toward CA IX or CA 
XII, we performed docking studies. For this purpose we chose Protein data bank (PDB) 
crystal structures derived from the wild-type CA isoforms and having a high resolution. 
CA I was modeled from PDB entry 1HCB, at 1.60 Å resolution20; CA II from 3B4F, at 
1.89 Å resolution21; CA IX from 3IAI, at 2.20 Å resolution22 and CA XII from 1JD0, at 
1.50 Å resolution.23 Some of those enzymes were co-crystallized with small molecule 
inhibitors. For the docking experiments we removed all small molecules and waters, 
neutralized proteins with counter-ions, than embedded them in water clusters and relaxed 
all structures by molecular dynamics minimization (see Experimental part for details). In 
this point reasonable question arise: are minimization of the protein structure upon bound 
ligand removal can cause collapse of the active site? We believe that regarding CAs this 
possibility is not an issue. CAs poses a wide and conical active site in significant extent 
exposed to solvent. During catalytic cycle, i.e. CO2 hydration, small changes of protein 
conformation is observed, and such changes mainly can be attributed to the His64 (proton 
shuttle) conformation change. Consequently, different from some other enzyme classes, 
CAs in their crystal structures are not ‘trapped’ in some local free-energy minimum for 
which another, close, local minimum can exist. Additionally, majority of CA inhibitors 
are medium-sized molecules, which typically did not significantly change conformation 
of active site, comparing to uninhibited protein. By visual inspection of the 3D structures 
of very efficient inhibitors (typically nanomolar, from the sulfonamide class) 
cocrystallized with the CAs it can be observed that such molecules typically did not 
interact with its whole molecular surface with the active site residues. Most probably this 
can be attributed to the wide CAs active site, as well as to very high affinity of ZBG to 
catalytic Zn2+ ion. On the other hand, from the modelling set-up view, it should be noted 
that MD minimization (as far as recent CHARMM force field variants and recent NAMD 
releases are used) commonly very limited mobility of backbone appears, while position 
of side-chains are usually efficiently relaxed. In all so far reported crystal structures of 
CA co-crystallized with small molecules having a -COOH group within enzyme active 
site, the water molecule bound to catalytic Zn2+ ion was present. Thus, for the docking 
study we added this water molecule. Initial position of the water was estimated from PDB 
entry 4E3G,13 para-hydroxybenzoyc acid co-crystallized with CA II, and further refined 
by the WaterFLAP protocol. All compounds were treated in their anionic forms, with 
  
deprotonated carboxyl group, in accordance with predicted and experimentally 
determined pKa values. Both tautomers A and B, Scheme 2, were used for docking. Initial 
attempts of docking compounds into the active site of each isoform appeared very 
inconclusive, so we proceeded considering the whole enzyme as a target. 
The docking study found all compounds bound out of the active site of CA I 
(Figure S4 in Supplementary Material), in the cleft lined by the residues Pro13, Asn24, 
Thr100 and His103. The carboxylate anion of these compounds makes polar interactions 
with Ser99 and Thr100 hydroxyl groups, while the pyrazole nitrogens make polar 
interactions with Asn245 side-chain and His103 backbone carbonyl. Larger alkyl 
substituents were typically anchored between side chains of Pro13 and Pro247. For CA 
II, the docking study also found majority of the compounds out of the active site (Figure 
S5 in Supplementary Material). The compounds are clustered in a region lined with 
residues: Trp5, Lys170, Asn232 and Pro237. The carboxylate anion makes polar 
interactions with His4 NH backbone and Lys170 side chain NH3+, whereas the pyrazole 
NH was hydrogen bounded with Phe231 backbone carbonyl. For CA I and CA II similar 
docking solutions were found irrespective of the position of the His64 (‘in’ or ‘out’). 
Such results revealed higher affinity of these compounds toward regions of CA I 
and CA II out of enzyme active site and can offer possible explanation of inactivity of 1-
23 toward these cytosolic CA isoforms studied here.  
Our docking study found all compounds bound close to the active site Zn2+ ion of 
CA IX and CA XII (including those for which Ki > 50 µM were measured). All 
compounds were clustered with very similar orientation of the pyrazole-COO– moiety in 
the active site of each isoform, but orientation of this part of the molecule appears 
different in CA IX and CA XII, respectively. In CA IX, the carboxylate anion makes 
polar interactions with the hydroxyl group of Thr199 and Thr200 and with the water 
coordinated to zinc. The pyrazole NH makes polar interactions with Gln67 side-chain 
carbonyl. As a trend, compounds found as active toward CA IX (Table 1) have alkyl 
substituents in ortho- and meta-positions of the phenyl ring. Compounds having bulkier 
substituents in para-position appeared to be inactive. Visual inspection of docking results 
revealed that ortho- and meta-substituted compounds, as well as those having medium-
sized alkyl substituents in para-position assessed better shape complementarily with the 
cleft of active site than the rest of the investigated compounds, which were inactive 
toward CA IX. This cleft is lined by backbone of residues Trp5, Asn62 and His64, and 
situated distal from the sequence 131-134. (Figure 3 and Figure S6 in Supplementary 
Material). These residues were shown earlier to be involved in the binding of various 
classes of CAIs or CA activators.24  
 
Figure 3.  
 
This observation could explain the structural features that differentiate active from 
inactive compounds towards CA IX. Along with this, we observed that compounds 9 
(2,3,5,6-tetra-methyl derivative) and 5 (4-t-butyl derivative) with Ki < 10 µM, have 
mutually very similar 3D-dependent whole-molecular properties, particularly apolar 
surface area and volume (Table S2 in Supplementary Material).    
Docking solutions for CA XII found all compounds close to the active site Zn2+ 
ion, but in orientations quite different compared to CA IX. The carboxylate anion makes 
  
polar interactions with Tyr7 and Thr199 hydroxyl groups, or Asn62 side-chain NH2. The 
pyrazole NH and N make polar interactions with Asn62 side-chain or water-mediated 
interactions with the Thr199. Aromatic moiety of the compounds were directed toward 
the sequence 131-134 (130’s segment). This part of the active site is specific for CA XII 
and it was suggested that can be used for the design of isoform specific inhibitors [23]. 
Visual inspection of the docking results showed that aryl moiety of all compounds found 
active towards CA XII makes van-der Walls contacts with the 130’s segment, while the 
same moiety in inactive compounds cannot reach this segment (Figure 4 and Figure S7 in 
Supplementary Material). This rationalizes the structure-activity relationship data of 1-23 
observed towards CA XII and shown in Table 1.  
 
Figure 4.  
 
It should be noted that we did not observe any regularity between calculated 
affinities of compounds (docking scores) and the order of activity toward CA IX or CA 
XII. ChemGauss4 scoring function accounts for shape and electrostatic 
complementarities, as well as the binding site and the ligand desolvation penalty. Not 
overall scoring, nor shape complementarities show any trend with the experimentally 
found Ki values. Considering the wide and conical shape of the CA active site, the 
congeneric set of examined compounds - different in apolar moieties only, and the 
narrow range of Ki values, such an observation is not surprising.    
In literature, we found one systematic comparison of CAs I, II, IX and XII active 
sites.25 CA active site residues involved in ligand binding were listed and similarity and 
differences commented. In order to elucidate more structural information that can explain 
selectivity of 1-23 toward membrane-associated isoforms, we studied active sites of CA I, 
II, IX and XII by GRID force field.26 Molecular interaction fields (MIF) were calculated 
by hydrophobic (DRY), HBD (N1) and HBA (O) probes in the box encompassing active 
site residues that interact with small molecules in so far reported crystal structures of CAs 
(for details see Experimental part and the Supplementary Material, file 2). Inspection of 
the results revealed expected differences of MIFs obtained with HBA and HBD probe (O 
and N1) in vicinity of residue 67 (Figure S8 in Supplementary Material). In this position 
mutually similar Asn of CA II or Gln of CA IX are replaced with His in CA I or Lys in 
CA XII. Less obvious difference appears by comparison of MIFs obtained by 
hydrophobic probe (DRY). In all four isoforms studied here, the global minimum of 
DRY probe, on about –3 kcal/mol, appears in vicinity of Pro202 - conserved in all four 
enzymes. On arbitrary chosen isocountour level of –0.7 to –0.9 kcal/mol, we observed 
‘continuous’ isosurface of DRY probe from the region of Pro202 to the region between 
Leu198 and Gln92  in CAs I, II and IX, Figure 5. 
 
Figure 5. 
  
In CA XII, DRY isosurface appears only in region of Pro202 and region between Leu198 
and Gln92, but those two isosurface are not mutually connected (Figure 5). Such a 
difference appears not only because significantly less voluminous, apolar Ala131 in CA 
XII, compared with Leu in CA I, Phe in CA II and Val in CA IX in this position; but also 
because of differences of residue in position 204, situated between Pro200 and Leu198. 
  
In CA I this is Ala, in CA II Leu, and in CA IX Tyr. All three residues can form 
hydrophobic interactions. In CA XII, the residue in position 204 is Asn that can make 
preferably polar interactions. To the best of our knowledge such differences among the 
four CA isoforms studied in this work were not explicitly described in literature so far, 
and can be used for design of isoform selective inhibitors by introduction of suitable 
hydrophobic/hydrophilic moiety relatively far from the ZBG. Probably because of 
feasibility of CA II crystallization, there are significantly less wild-type CA XII crystal 
structures comparing with CA II, or mimics of other isoforms derived by targeted 
mutations of CA II. Thus, in the literature so far, mainly differences in the 130’s segment 
have been exploited for the design of CA XII selective inhibitors. 
From our docking solutions of the four most potent derivatives toward CA XII 
(compounds 2, 4, 14, 15), we observed that their phenyl moieties fairly fit to DRY 
minima between Leu198 and Gln92 (Figure 6), while the same moieties of inactive 
derivatives are displaced from this region.    
 
Figure 6.  
 
Considering the activity of these compounds against CA IX and XII, the results 
obtained by our docking study and comparison of the four isoforms active sites suggested 
that more flexibility imposed to novel congeners will be desirable for increasing 
inhibitory potency, whereas bulkiness of phenyl substituents should be retained in order 
to have isoform selectivity toward CA XII. Having two rotatable bonds in the core 
structure (Ph-pyrazole-COOH), and substituents on the phenyl ring with the very limited 
conformational freedom (except in the 4-n-Bu derivative, 4), our compounds appeared 
relatively rigid. Thus, anchored near the Zn-bound water by the -COO– moiety, their 
hydrophobic moieties cannot simultaneously reach parts of the active site relatively far 
from the Zn2+ ion to make stronger non-covalent interactions. These conclusions may be 
useful for the design of novel congeners of CAIs incorporating carboxylate ZBGs.  
 
3 Conclusions 
 
We described the synthesis and inhibitory activity of a congeneric set of 23 phenyl-
substituted 5-phenyl-1H-pyrazole-3-carboxylic acids toward human CA isoforms I, II, IX 
and XII. The compounds were active in 4-50 µM range and showed strong preferences 
toward CA IX and XII over CA I and II. Due to such a selectivity, 5-aryl-pyrazole-3-
carboxylic acids reported in this work could be used for further development of isoform-
specific inhibitors. The results of our docking study offered possible explanations on the 
selectivity of these compounds toward CA IX and XII, as well as on their diverse affinity 
depending on the substitution pattern of the aryl moiety. Comparison of active sites of all 
four isoforms studied by GRID generated molecular-interaction fields revealed 
interesting differences between CA XII and other three isoforms in regions that have high 
affinity towards hydrophobic moieties. To the best of our knowledge such an observation 
was not reported so far and can foster development of the selective CA XII inhibitors.  
 
     
 
  
4 Experimental 
 
4.1 Chemistry: 
 
All chemicals were purchased from Fluka, Aldrich, or Merck, having >98% purity, and 
were used as received. For the thin-layer chromatography, silica gel pre-coated plates 
with fluorescent indicator (254 nm) were used. Melting points were determined in open 
capillary tubes on Stuart SMP-10 apparatus and are uncorrected. ESI-MS (Electrospray 
ionization mass spectrometry) analysis was performed in methanol on an Agilent 
Technologies 6210-1210 TOF-LC-ESI-MS instrument in positive mode. IR (Infra-red) 
spectra were recorded on a Thermo Nicolet 6700 FT-IC spectrophotometer, by ATR 
(Attenuated total reflectance). 1H, 13C NMR (Nuclear magnetic resonance) and NOESY 
(Nuclear Overhauser effect spectroscopy) spectra were recorded in DMSO-d6 on Bruker 
AVANCE 500/125 MHz or on a Varian Gemini2000 200/50 MHz instruments. Chemical 
shifts are reported in parts per million (ppm) relative to tetramethylsilane (TMS) and spin 
multiplicities are given as follows: s (singlet), d (doublet), t (triplet), q (quartet), qn 
(quintet), sx (sextet), h (heptet) m (multiplet), br (broad). UV/Vis Spectra were recorded 
on Thermo Scientific Evolution 60S spectrophotometer (Thermo Fisher Scientific Inc, 
Waltham, Massachusetts, USA). pH Values were measured using CRISON pH-Burette 
24 2S equipped with CRISON 50 29 micro-combined pH electrode (Crison Instruments, 
S.A. Spain). The electrode was calibrated by standard CRISON buffer solutions (pH 
4.01, 7.00, and 9.21). 
 
4.1.1 Typical experimental procedure for synthesis of 1-23 
 
5-(4-Methylphenyl)-1H-pyrazole-3-carboxylic acid (1): 0.4 g of 4-(4-methylphenyl)-2,4-
dioxobutanoic acid  [1] was dissolved in 20 ml of glacial acetic acid in 50 ml round- 
bottom flask. In a stirred solution, 280 µL (3 eq.) of hydrazine monohydrate (N2H4·H2O) 
was added dropwise. The color of solution was changed to pale yellow immediately after 
addition of first amount of hydrazine. The progress of reaction was monitored by TLC. 
After completion, reaction mixture was poured in 50 ml H2O and left to stir overnight. 
White precipitate was collected, dried on air and recrystallized from the mixture of 
hexane/EtOH (~ 9:1), giving 0.34 g of product (87 % of theoretical yield). 
 
4.1.2 Characterization of compounds 1-23 
 
5-(4-Methylphenyl)-1H-pyrazole-3-carboxylic acid. (1) White solid; m.p. = 253-254 °C 
(hexane/EtOH); C11H10N2O2, Mw = 202.21; ESI-MS: Calculated for C11H11N2O2 [M+H]+: 
203.08150, measured: 203.08063; IR (ν, cm-1): 3264 (N–H), 1696 (C=O), 1500, 1198; 1H 
NMR (500 MHz, DMSO-d6) δ (ppm): 2.30 (s, 3 H), 7.14 (s, 1 H), 7.22 (d, J = 7.83 Hz, 2 
H), 7.71 (d, J = 8.31 Hz, 2 H), 13.38 (br). 13C NMR (125 MHz, DMSO-d6) δ (ppm): 
20.85, 104.91, 125.25, 128.13, 129.48, 137.58, 140.09, 147.44, 162.04.  
 
5-(4-Ethylphenyl)-1H-pyrazole-3-carboxylic acid. (2) Starting from 0.625g of 4-(4-
ethylphenyl)-2,4-dioxobutanoic acid, 0.55 g of product was obtained (89% of theoretical 
yield). White solid; m.p. = 229-230 °C (hexane/EtOH); C12H12N2O2, Mw = 216.24; ESI-
  
MS: Calculated for C12H13N2O2 [M+H]+: 217.09715, measured: 217.09634; IR (ν, cm-1): 
3265 (N–H), 1692 (C=O), 1498, 1237; 1H NMR (200 MHz, DMSO-d6) δ (ppm): 1.17 (t, 
J
 
= 7.30 Hz, 3 H), 2.60 (q, J = 7.30 Hz, 2 H), 7.14 (s, 1 H) 7.26 (d, J=7.86 Hz, 2 H), 7.74 
(d, J = 8.42 Hz, 2 H), 12.93 (br); 13C NMR (50 MHz, DMSO-d6) δ (ppm): 15.74, 28.19, 
105.19, 125.60, 128.57, 140.48, 144.19, 147.67, 162.32.   
 
5-(4-Isopropylphenyl)-1H-pyrazole-3-carboxylic acid. (3) Starting from 0.095 g of 4-(4-
isopropylphenyl)-2,4-dioxobutanoic acid, 0.078 g of product was obtained (83% of 
theoretical yield). White solid; m.p. = 241-243 °C (hexane/EtOH); C13H14N2O2, Mw = 
230.26; ESI-MS: Calculated for C13H15N2O2 [M+H]+: 231.11280, measured: 231.11197. 
IR (ν, cm-1): 3229 (N–H), 1691 (C=O), 1499, 1194; 1H NMR (200 MHz, DMSO-d6) δ 
(ppm): 1.22 (d, J =  6.74 Hz, 6 H) 2.91 (h, J = 6.74 Hz, 1 H) 7.14 (s, 1 H) 7.31 (d, J = 
7.86 Hz, 2 H) 7.76 (d, J = 8.42 Hz, 2 H) 13.05 (br). 13C NMR (50 MHz, DMSO-d6) δ 
(ppm): 23.99, 33.43, 105.11, 125.58, 127.05, 128.78, 148.70, 162.27. 
 
5-(4-n-Butylphenyl)-1H-pyrazole-3-carboxylic acid. (4)  Starting from 0.52 g of 4-(4-n-
butylphenyl)-2,4-dioxobutanoic acid, 0.435 g of product was obtained (85% of 
theoretical yield). White solid; m.p. = 203-205 °C, dec. (hexane/EtOH); C14H16N2O2, Mw 
= 244.29; ESI-MS: Calculated for C14H17N2O2 [M+H]+: 245.12845, measured: 
245.12744. IR (ν, cm-1): 3320 (N–H), 1665 (C=O), 1455, 1265; 1H NMR (200 MHz, 
DMSO-d6) δ (ppm): 0.85 (t, J = 7.30 Hz, 3 H),  1.26 (sx, J1,2= 7.30 Hz, 2 H), 1.52 (qn, J 
= 7.30 Hz, 2 H), 2.55 (t, J = 7.30 Hz, 2 H), 7.14 (s, 1 H), 7.22 (d, J = 8.42 Hz, 2 H), 7.73 
(d, J = 7.86 Hz, 2 H), 13.09 (br); 13C NMR (50 MHz, DMSO-d6) δ (ppm): 14.03, 22.02, 
33.31, 34.87, 105.19, 125.54, 128.62, 129.09, 138.12, 142.77, 147.79, 162.38.  
 
5-(4-tert-Butylphenyl)-1H-pyrazole-3-carboxylic acid. (5) Starting from 0.62 g of 4-(4-
tert-butylphenyl)-2,4-dioxobutanoic acid, 0.48 g of product was obtained (79% of 
theoretical yield). White solid; m.p. = 257-259 °C, dec. (hexane/EtOH); C14H16N2O2, Mw 
= 244.29; IR (ν, cm-1): 3315 (N–H), 3145, 1723 (C=O), 1584, 1210; ESI-MS: Calculated 
for C14H17N2O2 [M+H]+: 245.12845, measured: 245.12888; 1H NMR (200 MHz, DMSO-
d6) δ (ppm): 2.50 (s, 9 H, overlapped with the solvent signal), 8.31 (s, 1 H), 8.65 (d, J = 
7.86 Hz, 2 H), 8.98 (d, J = 7.86 Hz, 2 H), 9.94 (br); 13C NMR (50 MHz, DMSO-d6) δ 
(ppm): 31.29, 34.56, 104.70, 125.29, 125.82, 129.20, 141.27, 148.25, 150.65, 162.78.  
 
5-(2,4-di-Methylphenyl)-1H-pyrazole-3-carboxylic acid. (6) Starting from 0.58 g of 4-
(2,4-di-methylphenyl)-2,4-dioxobutanoic acid, 0.49 g of product was obtained (86% of 
theoretical yield). White solid, m.p. = 248-249 °C (hexane/EtOH); C12H12N2O2, Mw = 
216.24;  ESI-MS: Calculated for C12H13N2O2 [M+H]+: 217.09715, measured: 217.09704; 
IR (ν, cm-1): 3099 (N–H, overlapped with C–H), 2975, 2917, 1695 (C=O), 1494, 1423, 
1279; 1H NMR (200 MHz, DMSO-d6) δ (ppm): 3.51 (s, 3 H), 3.58 (s, 3 H), 8.11 (s, 1 H), 
8.24 - 8.36 (m, 3 H; overlapped ortho-H doublet with meta-H signals (doublet and 
splitted singlet)), 8.62 (d, J = 7.86 Hz, 4 H), 14.29 (br). 13C NMR (50 MHz, DMSO-d6) δ 
(ppm): 20.93, 108.01, 126.94, 127.78, 129.08, 131.79, 135.56, 137.89, 140.56, 146.72, 
162.69.  
 
  
5-(3,4-di-Methylphenyl)-1H-pyrazole-3-carboxylic acid. (7) Starting from 0.38 g of 4-
(3,4-di-methyl phenyl)-2,4-dioxobutanoic acid, 0.33 g of product was obtained (88% of 
theoretical yield). White solid, m.p. = 276-277 °C (hexane/EtOH); C12H12N2O2, Mw = 
216.24;  ESI-MS: Calculated for C12H13N2O2 [M+H]+: 217.09715, measured: 217.09685; 
IR (ν, cm-1): 3107 (N–H, C–H), 2917, 1697 (C=O), 1508, 1469, 1270; 1H NMR (200 
MHz, DMSO-d6) δ (ppm): 2.24 (s, 3 H), 2.27 (s, 3 H), 7.15 (s, 1 H), 7.20 (d, J = 7.86 Hz, 
1 H), 7.57 (d, J = 7.86 Hz, 1 H), 7.65 (s, 1 H), 13.38 (br); 13C NMR (50 MHz, DMSO-d6) 
δ (ppm): 19.43, 19.71, 105.08, 122.99, 126.67, 128.58, 130.22, 136.63, 137.01, 140.60, 
147.62, 162.45.  
 
5-(2,4,5-tri-Methylphenyl)-1H-pyrazole-3-carboxylic acid. (8) Starting from 0.35 g of 4-
(2,4,5-tri-methylphenyl)-2,4-dioxobutanoic acid, 0.28 g of product was obtained (81% of 
theoretical yield). White solid, m.p. = 227-228 °C (hexane/EtOH); C13H14N2O2, Mw = 
230.26;   ESI-MS: Calculated for C13H15N2O2 [M+H]+: 231.11280, measured: 231.11234; 
IR (ν, cm-1): 3163, 3109 (N–H, overlapped with C–H), 1696 (C=O), 1514, 1277. 1H 
NMR (200 MHz, DMSO-d6) δ (ppm): 2.22 (s, 6 H), 2.33 (s, 3 H), 3.91 (pyrazole CH2 of 
tautomer C (Scheme 2), ~ 34% in respect to main tautomer), 6.88 (s, 1 H), 7.07 (s, 1 H), 
7.31 (s, 1 H), 13.33 (br); 13C NMR (50 MHz, DMSO-d6) δ (ppm): 19.20, 20.40, 51.64 
(pyrazole CH2 of tautomer C (Scheme 2)), 107.86, 127.80, 130.11, 132.32, 132.73, 
133.90, 136.56, 140.69, 146.57, 162.72.  
 
5-(2,3,5,6-tetra-Methylphenyl)-1H-pyrazole-3-carboxylic acid. (9) Starting from 0.37 g 
of 4-(2,3,5,6-tetra-methylphenyl)-2,4-dioxobutanoic acid, 0.33 g of product was obtained 
(91 % of theoretical yield). White solid, m.p. = 246-248 °C, dec. (hexane/AcOEt); 
C14H16N2O2, Mw = 244.29; ESI-MS: Calculated for C14H17N2O2 [M+H]+: 245.12845, 
measured: 245.12844; IR (ν, cm-1): 3244 (N–H), 3123, 2927, 1718 (C=O), 1471, 1410, 
1242; 1H NMR (500 MHz, DMSO-d6) δ (ppm): 1.88 (s, 6 H), 2.20 (s, 6 H), 6.57 (s, 1 H), 
7.05 (s, 1 H), 13.06 (br). 13C NMR (125 MHz, DMSO-d6) δ (ppm): 16.66, 19.69, 108.14, 
130.47, 131.65, 133.19, 142.40, 144.52, 163.03.  
 
 5-(2,4,6-tri-Ethylphenyl)-1H-pyrazole-3-carboxylic acid. (10) Starting from 0.41 g of 4-
(2,4,6-tri-ethylphenyl)-2,4-dioxobutanoic acid, 0.33 g of product was obtained (82% of 
theoretical yield). White solid, m.p. = 221-224 °C, dec. (hexane/AcOEt); C16H20N2O2, 
Mw = 272.34; ESI-MS: Calculated for C16H21N2O2 [M+H]+: 273.15975, measured: 
273.15938; IR (ν, cm-1): 3145 (N–H, broad), 2967, 1712 (C=O), 1460, 1263; 1H NMR 
(200 MHz, DMSO-d6) δ (ppm): 0.98 (t, J = 7.30 Hz, 6 H), 1.20 (t, J= 7.30 Hz, 4 H), 2.30 
(q, J1,2= 7.30 Hz, 4 H), 2.60 (q, J = 7.30 Hz, 2 H) 6.65 (s, 1 H) 7.00 (s, 2 H) 13.07 (br); 
13C NMR (50 MHz, DMSO-d6) δ (ppm): 15.88, 16.01, 26.63, 28.37, 108.77, 125.56, 
126.84, 143.48, 143.90, 144.97, 163.23.  
 
5-(2,4-di-Isopropylphenyl)-1H-pyrazole-3-carboxylic acid. (11) Starting from 0.35 g of 
4-(2,4-di-isopropylphenyl)-2,4-dioxobutanoic acid, 0.28 g of product was obtained (79% 
of theoretical yield). White solid, m.p. = 213-216 °C, dec. (hexane/AcOEt); C16H20N2O2, 
Mw = 272.34; ESI-MS: Calculated for C16H21N2O2 [M+H]+: 273.15975, measured: 
273.15940; IR (ν, cm-1): 3232 (N–H), 2962, 1704 (C=O), 1465, 1273; 1H NMR (200 
MHz, DMSO-d6) δ (ppm): 1.16 (d, J=6.74 Hz, 6 H), 1.22 (d, J=6.74 Hz, 6 H), 2.91 (h, 
  
J=6.74 Hz, 1 H), 3.20 (h, J= 6.74 Hz, 1 H), 6.75 (s, 1 H), 7.12 (d, splited J1,2 = 1.68 Hz, 
J1,3 =7.86 Hz, 1 H), 7.25 (d, b, J = 7.86 Hz, 1 H), overlapped with 7.28 (s, 1H), 13.26 
(br); 13C NMR (50 MHz, DMSO-d6) δ (ppm): 29.28, 33.74, 108.21, 123.74, 123.96, 
127.55, 130.17, 146.99, 149.43, 162.70 
 
5-(2,4,6-tri-Isopropylphenyl)-1H-pyrazole-3-carboxylic acid. (12) Starting from 0.32 g of 
4-(2,4,6-tri-isopropylphenyl)-2,4-dioxobutanoic acid, 0.21 g of product was obtained 
(66% of theoretical yield). ESI-MS: Pale yellow solid, m.p. = 217-219 °C, dec.  
(hexane/AcOEt); C19H26N2O2, Mw = 314.42; Calculated for C19H27N2O2 [M+H]+: 
315.20670, measured: 315.20693; IR (ν, cm-1): 3154 (N–H, C–H), 2961, 1700 (C=O), 
1567, 1461; 1H NMR (200 MHz, DMSO-d6) δ (ppm): 1.08 (d, J=6.74 Hz, 12H), 1.24 (d, 
J=6.74 Hz, 6 H), 2.49 (h, J=6.74 Hz, 1H, overlapped with DMSO-d6 signal), 2.92 (h, 
J=6.74 Hz, 1H), 3.82 (pyrazole CH2 of tautomer C (Scheme 2), ~ 36% in respect to main 
tautomer), 6.65 (s, 1H), 7.10 (s, 2H), 13.09 (br, 2H); 13C NMR (50 MHz, DMSO-d6) δ 
(ppm): 23.98, 30.20, 33.83, 51.53 (pyrazole CH2 of tautomer C (Scheme 2)), 108.83, 
120.40, 125.49, 148.16, 149.63, 163.13.  
 
5-(5,6,7,8-Tetrahydronaphthalen-2-yl)-1H-pyrazole-3-carboxylic acid.(13) Starting from 
0.51 g of 4-(5,6,7,8-tetrahydronaphthalen-2-yl)-2,4-dioxobutanoic acid, 0.41 g of product 
was obtained (82% of theoretical yield). White solid, m.p. = 234-236, dec. 
(hexane/EtOH); C14H14N2O2, Mw = 242.27; ESI-MS: Calculated for C14H15N2O2 [M+H]+: 
243.11280, measured: 243.11257; IR (ν, cm-1): 3104 (N–H, broad), 2925, 1697 (C=O), 
1430, 1270; 1H NMR (500 MHz, DMSO-d6) δ (ppm): 1.72 (m, b, 4 H) 2.70 (s, b, 2 H), 
2.74 (s, b, 2H) 7.07 - 7.09 (m, overlapped pyrazole CH singlet and meta-H doublet, 2 H) 
7.50 - 7.52 (m, overlapped ortho-Hs singlet and doublet, 2 H), 13.32 (br); 13C NMR (126 
MHz, DMSO-d6) δ (ppm): 22.71, 28.63, 28.87, 104.77, 122.54, 125.75 127.95, 129.42, 
136.82, 137.11, 140.38, 147.35, 162.12. 
 
5-(Naphthalen-2-yl)-1H-pyrazole-3-carboxylic acid. (14) Starting from 0.58 g of 4-( 
naphthalen-2-yl)-2,4-dioxobutanoic acid, 0.49 g of product was obtained (82% of 
theoretical yield). White solid, m.p. = 274-276 °C, dec. (hexane/AcOEt); C14H10N2O2, 
Mw = 238.24; ESI-MS: Calculated for C14H11N2O2 [M+H]+: 239.08150, measured: 
239.08065; IR (ν, cm-1): 3206 (N–H), 1683 (C=O), 1501, 1274; 1H NMR (200 MHz, 
DMSO-d6) δ (ppm): 7.23 (s, 1 H), 7.50 (t, J1,2= 3.93 Hz,  2 H), 7.89 (d, overlapped with 
doublet at 7.95, 1 H), 7.95 (d, J= 8.42 Hz, 2 H), 8.04 (d, J = 8.42 Hz, 1 H), 8.39 (s, 1 H); 
13C NMR (50 MHz, DMSO-d6) δ (ppm): 104.77, 123.81, 124.00, 126.23, 126.71, 127.93, 
128.31, 128.55, 130.40, 132.77, 133.50, 141.89, 149.21, 163.07. 
 
5-((1,1'-Biphenyl)-4-yl)-1H-pyrazole-3-carboxylic acid. (15) Starting from 0.50 g of 4-
((1,1'-biphenyl)-2-yl)-2,4-dioxobutanoic acid, 0.42 g of product was obtained (85% of 
theoretical yield). White solid, m.p. = 286-287 °C, dec. (hexane/AcOEt); C16H12N2O2, 
Mw = 264.28; ESI-MS: Calculated for C16H13N2O2 [M+H]+: 265.09715, measured: 
265.09653; IR (ν, cm-1): 3220 (N–H), 1657 (C=O), 1451, 1275; 1H NMR (200 MHz, 
DMSO-d6) δ (ppm): 7.28 (s, 1H), 7.36 (t, J = 7.30 Hz, 1 H), 7.46 (t, J = 7.86 Hz, 2 H), 
7.69 (d, 2 H, overlapped with doublet at 7.74), 7.74 (d, J = 7.86 Hz, 2 H), 7.95 (d, J = 
  
7.86 Hz, 2 H), 13.21 (br); 13C NMR (50 MHz, DMSO-d6) δ (ppm): 105.66, 126.13, 
126.84, 127.38, 127.89, 129.28, 130.40, 139.82, 140.00, 147.66, 162.14.  
 
5-(4-(Pyrrolidin-1-yl)phenyl)-1H-pyrazole-3-carboxylic acid. (16) Starting from 0.2 g of 
4-(4-(pyrrolidin-1-yl)phenyl)-2,4-dioxobutanoic acid, 0.16 g of product was obtained 
(81% of theoretical yield). Pale red solid, m.p. = 276-279 °C, dec. (hexane); C14H15N3O2, 
Mw = 257.29; ESI-MS: Calculated for C14H16N3O2 [M+H]+: 258.12370, measured: 
258.12359; IR (ν, cm-1): 3207 (N–H), 2963, 1711(C=O), 1616, 1515, 1189; 1H NMR 
(200 MHz, DMSO-d6) δ (ppm): 1.94 (br, t, 2 H), 3.24 (br, t, 2 H), 6.54 (d, J = 8.42 Hz, 2 
H), 6.91 (s, 1 H), 7.60 (d, J=8.42 Hz, 2 H), 8.91 (br); 13C NMR (50 MHz, DMSO-d6) δ 
(ppm): 25.17, 47.48, 103.04, 111.91, 118.28, 126.46, 142.10, 147.67, 147.94, 163.24.  
 
5-(4-Fluorophenyl)-1H-pyrazole-3-carboxylic acid. (17) Starting from 0.58 g of 4-(4-
fluorophenyl)-2,4-dioxobutanoic acid, 0.37 g of product was obtained (65% of theoretical 
yield). White solid, m.p. = 227-228 °C (hexane/AcOEt); C10H7FN2O2, Mw = 206.17;    
ESI-MS: Calculated for C10H8FN2O2 [M+H]+: 207.05643, measured: 207.05643; IR (ν, 
cm-1): 3334 (N–H), 3091, 1659 (C=O), 1453, 1240; 1H NMR (200 MHz, DMSO-d6) δ 
(ppm): 7.24 (s, 1 H), 7.30 (t, 3JHH=8.42 Hz, 3JHF = 8.99 Hz, 2H), 7.92 (dd, 3JHH = 8.42 Hz,  
4JHF = 5.05 Hz, 2 H) 11.81 - 14.42 (s, br); 13C NMR (50 MHz, DMSO-d6) δ (ppm): 
105.57, 115.84, 116.28, 127.56, 127.73, 128.20, 139.38, 147.74, 159.84, 161.92, 164.71.   
 
5-(4-Chlorophenyl)-1H-pyrazole-3-carboxylic acid. (18) Starting from 0.27 g of 4-(4-
chlorophenyl)-2,4-dioxobutanoic acid, 0.23 g of product was obtained (87% of 
theoretical yield). White solid, m.p. = 256-257 °C (hexane/AcOEt); C10H7ClN2O2, Mw = 
222.63; ESI-MS: Calculated for C10H8ClN2O2 [M+H]+: 223.02688, measured: 
223.02694; IR (ν, cm-1): 3188 (N–H), 1679 (C=O), 1488, 1271; 1H NMR (200 MHz, 
DMSO-d6) δ (ppm): 8.47 (s, 1 H) 8.71 (d, J=8.42 Hz, 2 H) 9.10 (d, J=8.99 Hz, 2 H); 13C 
NMR (50 MHz, DMSO-d6) δ (ppm): 105.86, 127.29, 129.18, 130.62, 132.88, 161.76, 
two low-intensity signals from pyrazole C=N and C–NH not observed. 
 
5-(3-Bromophenyl)-1H-pyrazole-3-carboxylic acid. (19) Starting from 0.57 g of 4-(3-
bromo phenyl)-2,4-dioxobutanoic acid, 0.45 g of product was obtained (80% of 
theoretical yield). White solid, m.p. = 249-251 °C (hexane/AcOEt); C10H7BrN2O2, Mw = 
267.08; ESI-MS: Calculated for C10H8BrN2O2 [M+H]+: 266.97637, measured: 
266.97587; IR (ν, cm-1): 3246 (N–H), 1694 (C=O), 1462, 1304; 1H NMR (200 MHz, 
DMSO-d6) δ (ppm): 7.35 (s, 1 H), 7.42 (t, J = 7.30 Hz, 1 H), 7.55 (d, J = 7.30 Hz, 1 H), 
7.90 (d, J=7.86 Hz, 1 H),  8.09 (s, 1 H), 13.43 (br); 13C NMR (50 MHz, DMSO-d6) δ 
(ppm): 106.23, 122.61, 124.58, 125.58, 128.00, 129.20, 131.04, 131.33, 161.70. 
 
5-(4-Hydroxyphenyl)-1H-pyrazole-3-carboxylic acid. (20) Starting from 0.46 g of 4-(4-
hydroxyphenyl)-2,4-dioxobutanoic acid, 0.39 g of product was obtained (87% of 
theoretical yield). White solid, m.p. = 282-283 °C, dec. (hexane/AcOEt); C10H8N2O3, Mw 
= 204.18; ESI-MS: Calculated for C10H9N2O3 [M+H]+: 205.06077, measured: 205.05983; 
IR (ν, cm-1): 3290 (N–H), 1679 (C=O), 1616, 1514, 1265; 1H NMR (200 MHz, DMSO-
d6) δ (ppm):  6.85 (d, J = 8.42 Hz, 2 H), 7.04 (s, 1 H), 7.67 (d, J = 8.42 Hz, 2 H), 9.80 
  
(br) 12.90 (br); 13C NMR (50 MHz, DMSO-d6) δ (ppm): 104.31, 115.95, 122.01, 127.07, 
141.07, 147.50, 157.90, 162.63.  
 
5-(2-Methoxyphenyl)-1H-pyrazole-3-carboxylic acid. (21) Starting from 0.40 g of 4-(2-
methoxyphenyl)-2,4-dioxobutanoic acid, 0.29 g of product was obtained (74% of 
theoretical yield). White solid, m.p. = 234-235 °C (hexane/AcOEt); C11H10N2O3, Mw = 
218.21; ESI-MS: Calculated for C11H11N2O3 [M+H]+: 219.07642, measured: 219.07644; 
IR (ν, cm-1): 3270, (N–H), 1708 (C=O), 1470, 1179; 1H NMR (200 MHz, DMSO-d6) δ 
(ppm): 3.91 (s, 3 H), 7.05 (t, J = 7.30 Hz, 1 H) 7.13 (d, overlapped with singlet at 7.17, 1 
H), 7.17 (s, 1 H), 7.37 (t, J
 
= 8.42, 1 H),  7.83 (dd, J1,2 = 7.86 Hz, J1,3 =1.68 Hz, 1 H), 
13.27 (br). 13C NMR (50 MHz, DMSO-d6) δ (ppm): 55.76, 108.19, 112.18, 118.79, 
120.97, 127.98, 129.91, 141.22, 142.86, 156.19, 162.98.  
 
5-(4-Methoxyphenyl)-1H-pyrazole-3-carboxylic acid. (22) Starting from 0.50 g of 4-(4-
methoxyphenyl)-2,4-dioxobutanoic acid, 0.45 g of product was obtained (92% of 
theoretical yield). White solid, m.p. = 226-228 °C, dec. (hexane/AcOEt); C11H10N2O3, 
Mw = 218.21; ESI-MS: Calculated for C11H11N2O3 [M+H]+: 219.07642, measured: 
219.07540; IR (ν, cm-1): 3309, 3249 (N–H), 1679 (C=O), 1456, 1206; 1H NMR (200 
MHz, DMSO-d6) δ (ppm): 3.77 (s, 3 H) 6.99 (d, J = 8.99 Hz, 2 H), 7.09 (s, 1 H), 7.76 (d, 
J = 8.42 Hz, 2 H), 13.21 (br); 13C NMR (50 MHz, DMSO-d6) δ (ppm): 55.45, 104.75, 
114.60, 123.70, 127.00, 140.62, 147.45, 159.57, 162.43.  
 
5-(4-Methoxy-2,5-dimethylphenyl)-1H-pyrazole-3-carboxylic acid. (23) Starting from 
0.62 g of 4-(4-methoxy-2,5-dimethylphenyl)-2,4-dioxobutanoic acid, 0.54 g of product 
was obtained (89% of theoretical yield). Pale yellow solid, m.p. = 232-234 °C, dec. 
(hexane/AcOEt); C13H14N2O3, Mw = 246.26; ESI-MS: Calculated for C13H15N2O3 
[M+H]+: 247.10772, measured: 247.10769; IR (ν, cm-1): 3304, 3164 ( N–H), 1695 
(C=O), 1510, 1430, 1238; 1H NMR (200 MHz, DMSO-d6) δ (ppm): 2.14 (s, 3 H), 2.36 (s, 
3 H), 3.81 (s, 3 H), 6.81 (s, 1 H), 6.87 (s, 1 H), 7.27 (s, 1 H), 13.08 (br); 13C NMR (50 
MHz, DMSO-d6) δ (ppm): 15.77, 20.96, 55.56, 107.68, 112.89, 122.74, 123.27, 131.17, 
134.65, 140.82, 146.27, 157.42, 162.83.  
 
Representative 1H and 13C NMR spectra are provided in Supplementary Material, Figures 
S10-S31.   
 
 
4.1.3 Determination of acidity constant 
 
The acidity constant (pKa1) value of 4-MeO derivative (22) was determined using 
spectrophotometric titration at 25±1 °C. The 50.0 ml of 1×10-4 M working solution was 
prepared in 10 mM phosphate buffer, pH=1.73, I=0.1 M (NaCl) and titrated with 1M 
KOH till pH 6 was reached (total volume change was less than 1% at the end of titration). 
UV/Vis spectra were recorded in 220-420 nm range against the phosphate buffer as a 
blank. pKa1 Value was calculated according to equation:27 
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Where )( −AAλ  is the absorbance of pure deprotonated compound (-COO
–), )(ΗΑΑλ is 
absorbance of molecular form (-COOH), and Aλ is the absorbance of solutions at different 
pH values where both forms of compound 22 exist in the solution.  
 
4.2 CA Inhibition 
 
An SX.18MV-R Applied Photophysics stopped-flow instrument was used for assaying 
the CA-catalyzed CO2 hydration activity by using the method of Khalifah.28 Inhibitor and 
enzyme were preincubated for 15 min prior to assay. IC50 Values were obtained from 
dose response curves working at seven different concentrations of test compound (from 
0.1 nM to 100 µM), by fitting the curves using PRISM (www.graphpad.com) and non-
linear least squares methods. The obtained values represent the mean of at least three 
different determinations, as described earlier by us.29,30 The inhibition constants (Ki) were 
then derived by using the Cheng-Prusoff equation, as follows: Ki = IC50/(1 + [S]/Km), 
where [S] represents the CO2 concentration at which the measurement was carried out, 
and Km the concentration of substrate at which the enzyme activity is at half maximal. All 
enzymes used were recombinant, produced in E.coli as reported earlier.31,32,33,34 The 
concentrations of enzymes used in the assay were: hCA I, 12.3 nM; hCA II, 7.7 nM; hCA 
IX, 9.9 nM and hCA XII, 12.3 nM. 
 
4.3 Molecular modeling 
 
Structures of compounds 1-23, in its anioic form, were prepared in SMILES notation 
(simplified molecular-input line-entry system). Both tautomers A and B (Scheme 2) were 
considered. Conformers of the each compound was generated in OMEGA 2.4.3, 35 using 
MMFF94s force field (build and search) and default settings.36  With the exception of the 
4-n-Bu derivative (4), conformation assemblies per molecule did not exceed 50 
conformations. The use MMFF94s force filed without Coulomb interaction (NoEstat); 
and/or decrease of root-mean-square (rms) value of atomic positions between conformers 
that should be included in conformational assembly, comparing to OMEGA default 
settings, did not produced more conformers per molecule. Carbonic anhydrases were 
modeled from the following PDB entries: CA I - 1HCB, CAII - 3BF4, CAIX - 3IAI and 
CAXII - 1JD0. The one subunit (subunit A), of the CAIX and CAXII was used, and 
water and other small molecules were removed from all structures used for modelling. 
Protonation states of His residues was adopted from PDB entry 4G0C,37 obtained by 
neutron diffraction. His64 was treated as a neutral, with protonated delta N. In the input 
PDB files, protonation states of histidine residues were specified by appropriate residue 
names, following CHARMM convention (HSD or HSE). Hydrogens of other atoms are 
ascribed automatically during proteins preparation using CHARMM-GUI.38 Protonation 
states of ionizable residues other than His was subsequently visually checked and 
compared with protonation states of 4G0C structure. Each protein was neutralized by 
addition of counter-ions and embedded in water sphere surrounding protein by 10 Å layer 
  
from the edges. CHARMM36 parameters were ascribed by CHARMM-GUI. Each 
protein was submitted to three cycles of minimization (minimization - heating- 
minimization…) during 20 ps each, without any restrains, in NAMD2.9.39 Conjugate 
gradient minimizer was used. In this way obtained protein structures were used for 
docking studies and for comparison of active sites. For docking studies Zn-bound water 
molecule was added. Docking of compounds 1-23 to all four proteins were performed by 
FRED 3.0.140,41 with docking resolution set to high, without any constraint. The whole 
protein, considered as the receptor, was prepared in OpenEye ‘MakeReceptor’ graphical 
user interface. Both His64 ‘in’ and ‘out’ conformation was considered in each protein, in 
separate docking runs. Ten top-ranked docking solutions were used for analysis. For the 
comparison of active sites proteins are aligned by their α-traces using DaliLight web 
interface.42,43 GRID26 molecular interaction fields (MIFs) with hydrophobic (DRY), HBD 
(N1), and HBA (O) probes, were calculated in FLAP2.1.44,45 Grid resolution was set to 
0.5 Å. MIFs were calculated in the box encompassing following residues (1JD0 residues 
numbering): Trp5, Thr60, Asn62, His64, Lys67, Asn69, Gln92, His94, His96, His119, 
Val121, Ala131, Ser132, Thr133, Ala134, Val143, Leu198, Thr199, Thr200, Pro202 and 
the Zn2+ ion, for the each protein and having exactly the same size. Box used for the 
GRID calculation, along with the important residues labeled, on the example of hCA XII, 
is depicted in Supplementary Material, Figure S9. The same box and the field of DRY 
probe on isocountour level of –0.7 kcal/mol is enclosed as a PyMol state file 
(Supplementary Material, file 2). The 3D-dependent whole molecular properties (Surface 
area, Polar surface area, Apolar surface area, Volume and VirtualLogP 46) of compounds 
1-23 in its anionic forms were calculated in VegaZZ 3.0.547 from structures optimized by 
semiempirical molecular-orbital PM6 method,48 as applied in MOPAC2012.49 For the 
calculation of 3D-dependent molecular properties, probe with radius of 0 Å was used. 
VegaZZ were also used for handling of protein structures and for set-up and analysis of 
MD calculations. MD and docking calculations were performed on Linux-based multi-
node clusters equipped with the Intel Xeon E5345, or X5560 processors.50 Figures from 
FLAP or FRED outputs were prepared in PyMol 1.7.051 or VIDA 4.2.1. 2D depictions 
provided in Supplementary Material were made by OpenEye OEDepictTK. 
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Table, Schemes and Figures Captions: 
 
Table 1. Structures of compounds 1-23 and inhibitory activities (given as Ki) toward four 
CA isoforms. 
 
Scheme 1. Synthesis of 5-aryl-1H-pyrazole-3-carboxylic acids. (a) CH3COCl, 
AlCl3/CH2Cl2, 6h, 0°C to rt; (b) 2 eq. Na/CH3OH, 15h, rt, then conc. HCl, (c) 
N2H4·H2O/CH3COOH, 8h, rt. 
 
Scheme 2. Tautomers of aryl-pyrazole-carboxylic acids 
 
Figure 1. NOESY spectrum of 4-Me-derivative (1) in DMSO. Signal between ortho-Ph-
hydrogens and pyrazole NH is illustrated. 
 
Figure 2. a) UV/Vis Spectra of compound 22 in pH range 1.73-5.68 used for pKa1 
determination (t=25±1 °C); wavelength range used for calculations is magnified; b) 
Determination of Ka1 at 280 nm according to Equation 1; slope = 4.0±0.2×10-4, intercept 
= 0.764±0.003, r2 = 0.973. 
 
Figure 3. Best-ranked solutions of compounds 9 (a) and 11 (b) docked into CAIX. 
 
Figure 4. Best-ranked solutions of compounds 15 (a) and 14 (b) docked into CAXII. 
 
Figure 5. Isosurface of DRY molecular-interaction field in the active site of CAI, II, IX 
and XII, depicted on –0.7 kcal/mol. a) Comparison between CAXII (blue solid field, grey 
sticks) and CAI (red mesh field, yellow sticks). b) Comparison between CAXII (blue 
solid field, grey sticks) and CAII (red mesh field, orange sticks). c) Comparison between 
CAXII (blue solid field, grey sticks) and CAIX (red mesh field, green sticks).  Pro202, 
conserved in the each CA isoform studied, and residues in position 204 are labeled. 
Among other residues shown, residues of 130s’ segment (residues 131-134) on the left 
side and His residues which coordinates active site Zn2+ ion (94, 96 and 119) on the right 
side are given in stick presentation, without explicit labels; while active site Zn2+ ion is 
given as the orange sphere.  
 
 
Figure 6. Best-ranked docking solutions for compounds 4 (yellow sticks), 14 (green 
sticks) and 15 (red sticks) overlapped with the isosurface of DRY probe (–0.7 kcal/mol) 
in the CA XII active site. Pro202 and Asn204, given in stick presentation, are labeled. 
Among other residues shown, residues of 130s’ segment (residues 131-134) on the left 
side and His residues which coordinates active site Zn2+ ion (94, 96 and 119) on the right 
side are given in stick presentation, without explicit labels; while active site Zn2+ ion is 
given as a red sphere.  
 
 
 
  
Table 1. Structures of compounds 1-23 and inhibitory activities (given as Ki) toward four 
CA isoforms. 
 
Compound R- 
Ki (µM)* 
hCA I hCA II hCA IX hCA XII 
1 4-Me- >50 >50 >50 >50 
2 4-Et- >50 >50 42 4.5 
3 4-i-Pr- >50 >50 >50 >50 
4 4-n-Bu- >50 >50 39 5.5 
5 4-t-Bu- >50 >50 5 21 
6 2,4-di-Me- >50 >50 45 >50 
7 3,4-di-Me- >50 >50 48 >50 
8 2,4,5-tri-Me- >50 >50 23.5 >50 
9 2,3,5,6-tetra-Me- >50 >50 5 >50 
10 2,4,6-tri-Et- >50 >50 >50 >50 
11 2,4-di-i-Pr- >50 >50 16 >50 
12 2,4,6-tri-i-Pr- >50 >50 39 39 
13 β-Tetralinyl- >50 >50 >50 43.5 
14 β-Naphtyl- >50 >50 >50 5.5 
15 4-Ph- >50 >50 >50 4 
16 4-Pyrrolidine- >50 >50 >50 33.5 
17 4-F- >50 >50 >50 38.5 
18 4-Cl- >50 >50 >50 50 
19 3-Br- >50 >50 23.5 >50 
20 4-OH- >50 >50 >50 41 
21 2-OMe- >50 >50 >50 50 
22 4-OMe- >50 >50 49.5 >50 
23 4-OMe-2,5-di-Me- >50 >50 22.5 >50 
AAZ** / 0.25 0.012 0.025 0.006 
*Mean from three different assays, errors in the range of 5-10% of the reported values (data not 
shown). 
**Acetazolamide (5-acetamido-1,3,4-thiadiazole-2-sulfonamide, AAZ) was used as a standard 
inhibitor. 
 
 
 
 
  
 
 
Scheme 1. Synthesis of 5-aryl-1H-pyrazole-3-carboxylic acids. (a) CH3COCl, 
AlCl3/CH2Cl2, 6h, 0°C to rt; (b) 2 eq. Na/CH3OH, 15h, rt, then conc. HCl, (c) 
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Figure 2. a) UV/Vis Spectra of compound 22 in pH range 1.73-5.68 used for pKa1 
determination (t=25±1 °C); wavelength range used for calculations is magnified; b) 
Determination of Ka1 at 280 nm according to Equation 1; slope = 4.0±0.2×10-4, intercept 
= 0.764±0.003, r2 = 0.973. 
 
 
a) b) 
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a) b) 
Figure 4. Best-ranked solutions of compounds 15 (a) and 14 (b) docked into CAXII. 
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Figure 5. Isosurface of DRY molecular-interaction field in the active site of CAI, II, IX 
and XII, depicted on –0.7 kcal/mol. a) Comparison between CAXII (blue solid field, grey 
sticks) and CAI (red mesh field, yellow sticks). b) Comparison between CAXII (blue 
solid field, grey sticks) and CAII (red mesh field, orange sticks). c) Comparison between 
CAXII (blue solid field, grey sticks) and CAIX (red mesh field, green sticks). Pro202, 
conserved in the each CA isoform studied, and residues in position 204 are labeled. 
Among other residues shown, residues of 130s’ segment (residues 131-134) on the left 
side and His residues which coordinates active site Zn2+ ion (94, 96 and 119) on the right 
side are given in stick presentation, without explicit labels; while active site Zn2+ ion is 
given as the orange sphere.  
 
 
  
Figure 6. Best-ranked docking solutions for compounds 4 (yellow sticks), 14 (green 
sticks) and 15 (red sticks) overlapped with the isosurface of DRY probe (–0.7 kcal/mol) 
in the CA XII active site. Pro202 and Asn204, given in stick presentation, are labeled. 
Among other residues shown, residues of 130s’ segment (residues 131-134) on the left 
side and His residues which coordinates active site Zn2+ ion (94, 96 and 119) on the right 
side are given in stick presentation, without explicit labels; while active site Zn2+ ion is 
given as a red sphere.  
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